- Human pathology

Home > A. Molecular pathology > Targeted therapy > Pathway-targeted therapy > mTOR pathway inhibitors

mTOR pathway inhibitors

Saturday 27 May 2017

mTOR inhibitors; PI3K/AKT/ mTOR pathway

By cancer

- mTOR pathway inhibitors in breast cancer

  • Breast cancer is the most commonly diagnosed cancer in women.
  • The PI3K/AKT/ mTOR pathway is among the most frequently dysregulated pathways in patients with breast cancer.
  • The activation of this pathway is associated with increased cell growth and clinical outcome, and its overexpression is associated with a poor prognosis.
  • It has been proposed that it may be of importance as a potential therapeutic target in the treatment of breast cancer.

Open references

- mTOR function and therapeutic targeting in breast cancer.
Hare SH, Harvey AJ.
Am J Cancer Res. 2017 Mar 1;7(3):383-404.
PMID: 28400999 Free

Paywall References

- The therapeutic potential of PI3K/Akt/mTOR inhibitors in breast cancer: rational and progress. Bahrami A, Khazaei M, Shahidsales S, Hassanian SM, Hasanzadeh M, Maftouh M, Ferns GA, Avan A. J Cell Biochem. 2017 May 17. doi : 10.1002/jcb.26136 PMID: 28513879